AV Remdesivir
32283108 ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
32020029 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
32378648 2020. Rapid review for the anti-coronavirus effect of remdesivir
32147516 ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections
32333086 ä. Remdesivir bei Patienten mit schwerer COVID-19
32361744 ä. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease
32275812 ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19
32284326 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
32094225 2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
32258351 2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
32054787 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
32239125 2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2
32358203 ä. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
